Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018, 378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
Advertisement
Articles by Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018, 378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
Advertisement
Latest Updated Articles
- Study Summary: Use of Enzalutamide for High-Risk, Nonmetastatic, Castration-Resistant Prostate Cancer (PROSPER)
Published: November 9th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
4
As Milestone Nears, an Early Investigator Reflects on Lessons of Imatinib
5
